UCB Advances Psoriasis Pipeline with Positive Data at American Academy ...
(WorldNews Belgium)

Oral presentation of Phase 2b findings for bimekizumab in the treatment of moderate-to-severe chronic plaque psoriasis patients will focus on the effects of dual neutralization of both IL-17A and IL-17F Three pooled sub-analyses from ongoing, Phase 3 studies CIMPASI-1, CIMPASI-2 and CIMPACT reflect potential versatility of CIMZIA® (certolizumab pegol) in the treatment of psoriasis Results from the largest cohort of pregnant women exposed to an anti-TNF for management of a chronic inflammatory disease highlight the value of CIMZIA for this underserved population Brussels, Belgium - February 16, 2018 - UCB, a global biopharmaceutical company, will be presenting new data on CIMZIA®...